Objective To characterize subclinical abnormalities in asymptomatic heterozygote NPC1 mutation carriers as marker of neurodegeneration. Methods Motor function, cognition, mood, sleep, and smell function were assessed in 20 first-degree heterozygous relatives of NPC patients (13M, age 52.7 ± 9.9 yrs). Video-oculography (VOG) and abdominal ultrasound with volumometry were performed to assess oculomotor function, size of liver and spleen. NPC-biomarkers in blood were analyzed. 18F-fluorodesoxyglucose positron emission tomography (FDG-PET) was performed (n=16) to detect patterns of brain hypometabolism. Results NPC heterozygotes recapitulate characteristic features of symptomatic NPC disease: They demonstrated the oculomotor abnormalities typical for NPC. Hepatosplenomegaly (71%) and increased cholestantriol (33%) and plasma chitotriosidase (17%) levels were present. They also showed signs seen in other neurodegenerative disease including hyposmia (20%) or pathological screening for REM sleep behaviour disorder (24%). Cognitive function was frequently impaired, especially affecting visuoconstructive function, verbal fluency and executive function. PET imaging revealed significantly decreased glucose metabolic rates in 50% of subjects, affecting cerebellar, anterior cingulate, parietooccipital and temporal regions, including one with bilateral abnormalities. Conclusion NPC heterozygosity, which has a carrier frequency of 1:200 in the general population, is associated with abnormal brain metabolism and functional consequences. Clinically silent heterozygous gene variations in NPC1 may be a risk factor for late-onset neurodegeneration, similar to the concept of heterozygous GBA mutations underlying Parkinson disease.